Skip to main content

Spatial and Metabolic Dimensions of Immunosuppression in the Solid Tumor Microenvironment

Cover image for Research Topic "Spatial and Metabolic Dimensions of Immunosuppression in the Solid Tumor Microenvironment"
33kviews
Editorial: Spatial and metabolic dimensions of immunosuppression in the solid tumor microenvironment
Editorial26 October 2026
Editorial: Spatial and metabolic dimensions of immunosuppression in the solid tumor microenvironment

Immunosuppression in solid tumors is not governed by a single cell type or signaling pathway. Instead, it arises from interactions among tumor cells, immune cells, and stromal cells within specific microenvironmental contexts (1,2) . The functions of cell populations such as regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and cancer-associated fibroblasts (CAFs) are jointly shaped by their spatial neighborhoods and local metabolic conditions (3,4) . The net impact of these cell populations is context dependent. They may promote tumor immune evasion, but may also restrain harmful inflammation or support antitumor immunity (2,5,6) . Based on this understanding, this Research Topic brings together nine original research articles and four reviews spanning multiple levels, including spatial effects, metabolic niches, and clinical implications, collectively advancing our understanding of the multiscale features of immunosuppression in solid tumors.

Cellular location and intercellular interactions are important determinants of immune functional states (3) . Cai et al. integrated spatial transcriptomic data across multiple cancer types and found that COL11A1⁺ CAFs tend to accumulate at tumor boundaries and are associated with the reduced signatures of activated cytotoxic T cells and B cells, suggesting that they may participate in establishing boundaries that restrict immunecell entry into tumors. Using multiplex immunofluorescence, Sun et al. found in nonsmall cell lung cancer that a spatial neighborhood composed of BAG3⁺IFITM2⁺ CAFs and BAG3⁺CD8⁺ T cells was associated with resistance to neoadjuvant chemoimmunotherapy. Notably, this configuration represents a setting in which CD8⁺ T cells are present but embedded within a specific CAF-associated stromal neighborhood. However, spatial proximity does not necessarily equate to functional interaction. For example, MUC16 can inhibit conjugation between NK cells and ovarian cancer cells and the formation of effective immune synapses (7) . Furthermore, spatial organization is not static. In their review of prostate cancer, Xue et al. proposed a framework of tumor-immune spatiotemporal co-evolution and discussed how tumor progression and therapy-imposed selective pressures can continuously alter tumor clones, stromal architecture, and immune composition. Therefore, future spatial maps need to move beyond simply describing cell locations toward resolving dynamic functional niches jointly constituted by cellular states, tissue architecture, and intercellular interactions.

Spatial organization and metabolic states are not independent of one another (4,8) . Spatial transcriptomic analyses by Cai et al. also identified co-localization of COL11A1⁺ CAF and lipid-associated macrophage signatures, suggesting a possible link between tissue organization and metabolism-associated cellular states. Factors such as abnormal vasculature, hypoxia, and nutrient competition create regional heterogeneity in nutrients and metabolites and selectively support distinct cellular states (9)(10)(11) . In microsatellite-stable gastric cancer, Lin et al. identified a lactylation-related gene signature that was associated with PDGFRA⁺ and CA9⁺ CAF states, hypoxia and extracellular matrix remodeling, and computationally predicted immune exclusion and dysfunction. Zheng further summarized amino acid, lipid, and glucose metabolic reprogramming in osteosarcoma-macrophage interactions, illustrating that metabolites can participate in TAM reprogramming, T-cell suppression, pre-metastatic niche formation, and treatment resistance. Liu further integrated lactate and acidosis, the hypoxia-adenosine axis, tricarboxylic acid-cycle metabolites, and mitochondrial damage signals as metabolic pressures that affect the adaptive capacity of different immune cells, and proposed the concept of "immune sorting," whereby the microenvironment does not uniformly suppress all immune cells but selectively favors immune-cell states capable of remaining functional under the corresponding metabolic pressures. Meanwhile, Huang et al. used transcriptome-based metabolic modeling to infer increased glycolysis, fatty acid oxidation, tricarboxylic acid-cycle activity, and amino acid metabolism in high R-loop prognostic index (RLPI) glioma cells, alongside computational associations with immune infiltration and immunosuppressive signaling. Using genetic and Mendelian randomization analyses, Wu et al. further linked brain microstructure and cross-compartment metabolic features to glioma susceptibility, extending the scale at which spatial-metabolic interactions are considered. These studies suggest that metabolic reprogramming can generate local immune selection pressures and may also interact with tissue environments at larger scales.

The immunological significance of cells or molecules within the tumor microenvironment cannot be defined independently of their specific context. Beyond previous studies on IL18BP (12,13) , the review by Huang et al. provides a representative example: by limiting receptor-accessible free IL-18, IL18BP can attenuate NK-cell-and T-cell-mediated antitumor responses; when IL-18 participates in chronic inflammation, immune tolerance, or metastatic adaptation, its neutralization may produce different biological consequences. Zhao et al. showed that extracellular vesicles from coal duststimulated macrophages promoted thyroid cancer cell proliferation and invasion in vitro and tumor growth in xenograft models, highlighting the context-dependent effects of macrophage-mediated communication on tumor progression. This context dependence also suggests that we need to shift from seeking universal single immune or metabolic biomarkers toward identifying the current immune ecosystem state of a tumor and its dominant limiting factors (14,15) . Sun et al. found that the BAG3⁺ CAF-T-cell neighborhood was associated with pathological non-response to neoadjuvant chemoimmunotherapy and showed greater discriminatory performance than either BAG3⁺IFITM2⁺ CAFs or BAG3⁺CD8⁺ T cells alone, suggesting that spatial relationships may provide information beyond individual cell populations. Peng et al. further showed that a Treg-rich state could be indirectly predicted by computational models based on routine H&E histomorphology, demonstrating the potential to extract information encoded in tissue morphology from whole-slide images and further translate complex microenvironmental information into accessible indicators (16) .These observations further underscore the practical need for clinically meaningful stratification. In retrospective analyses, the high RLPI defined by Huang et al. was associated with poorer responses to radiotherapy and temozolomide in lower-grade glioma, alongside increased computationally estimated immune-cell infiltration and immune-checkpoint gene programs. By contrast, a higher index was associated with more favorable responses to immune checkpoint inhibitors in independent cohorts of other cancer types. These findings suggest that different microenvironmental states may expose distinct therapeutic vulnerabilities. Complementing this molecular-stratification perspective, Yang et al. developed a five-gene parthanatos-related prognostic model in lung adenocarcinoma. The resulting risk groups differed in computationally estimated immune-cell infiltration and immune-checkpoint gene expression. The retrospective gastric cancer cohort study by Li et al. further illustrated, at the level of clinical endpoints, the importance of accurately identifying patients with potential non-response before treatment. Meanwhile, the reviews by Xue and Liu integrated evidence suggesting that treatment pressure, while eliminating sensitive cells, may simultaneously select or reshape new metabolic, stromal, and immune states. Therefore, future clinical translation should move beyond single-marker stratification toward dynamic biomarkers based on spatial effects, metabolic state, and intercellular interactions.

This Research Topic demonstrates the multiscale features of immunosuppression in solid tumors from multiple perspectives, including spatial effects, metabolic adaptation, and clinical implications. These studies emphasize that the net effect of immune regulation is jointly influenced by cellular states, spatial neighborhoods, and metabolic resources. Viewed in the broader context of existing mechanistic evidence, these contributions offer complementary perspectives on the interplay among these dimensions. Spatial effects may shape local metabolic pressures, while metabolic reprogramming may, in turn, reshape cellular states and spatial interactions. This dynamic interplay might influence the context-dependent balance between immunosuppression and antitumor immunity, with implications for therapeutic responses (Figure 1) (17)(18)(19) . The key challenge ahead is to further determine how specific microenvironmental conditions alter the net impact of immune cells and to construct spatially resolved, cross-scale maps of tumor-immune ecosystems.Ultimately, translating these findings into stratification tools and selective intervention strategies could help advance precision cancer therapy.

724 views

ORIGINAL RESEARCH
14 October 2026
Coal dust-stimulated macrophage-derived extracellular vesicles promote thyroid cancer cell phenotypes involving miR-205-5p, CAMK1G, and NF-κB-associated signaling
Feng Zhao, 2 more and Hongzhen Zhang

673 views

BAG3+ CAF-T cell neighborhood predicts resistance to neoadjuvant chemoimmunotherapy in NSCLC
ORIGINAL RESEARCH
7 July 2026
BAG3+ CAF-T cell neighborhood predicts resistance to neoadjuvant chemoimmunotherapy in NSCLC
Jing Sun, 10 more and Ziming Li
BackgroundDespite significantly improving outcomes in non-small cell lung cancer (NSCLC), neoadjuvant chemoimmunotherapy (NCIT) fails to achieve a major pathological response (MPR) in over 40% of patients. Consequently, the early identification of non-responders prior to treatment initiation remains a critical unmet clinical need.MethodsIn this study, we performed single-cell RNA sequencing (scRNA-seq) on pre-treatment NSCLC tissue samples and integrated data from two public databases to identify signaling pathways associated with poor treatment response. Key findings were subsequently validated using multiplex immunofluorescence (mIF), and the predictive value of identified molecules was finally assessed in our cohort and GEO datasets.ResultsAmong the 83 patients, 23/57 (40.35%) of these radiological responders failed to achieve MPR. Data analysis revealed activation of stress-related signaling pathways in cancer-associated fibroblasts (CAFs) and T cells from nMPR patients, with elevated expression of stress-related markers, including BAG3 and IFITM2. MIF confirmed that BAG3+IFITM2+ CAFs and BAG3+CD8+ T cells were spatially adjacent and significantly more abundant in nMPR patients. In our cohort and the two public databases, the BAG3+ CAF-T Cell Neighborhood was significantly more abundant in the nMPR group compared to the MPR group (p<0.05). In the MPR group, there was no significant difference in BAG3+ CAF-T Cell Neighborhood between the radiological PR and non-PR subgroups. The AUC values of BAG3+IFITM2+ CAFs, BAG3+CD8+ T cells, and the BAG3+ CAF-T Cell Neighborhood were 0.84 [95%CI: 0.746-0.931], 0.72 [95%CI: 0.603-0.835], and 0.87 [95%CI: 0.787-0.948], respectively. The OS and DFS of the BAG3+ CAF-T Cell Neighborhood high group are significantly decreased than that of the low group (p<0.05). The level of BAG3+ CAF-T Cell Neighborhood outperformed other two indicators in predicting non-response to NCIT. Consistent results were observed in GSE126044 and GSE135222.ConclusionThe BAG3+ CAF-T Cell Neighborhood may serve as a biomarker for predicting non-response to NCIT in NSCLC, with significant potential to inform clinical decision-making.

1,493 views

2 citations

ORIGINAL RESEARCH
3 July 2026
Imaging-mediated genetic effects link brain microstructure, metabolic profiles, and regional transcription to glioma susceptibility
Yufan Wu, 5 more and Jinsheng Hong

1,531 views

Identification of a lactylation-related gene signature in microsatellite stable gastric cancer based on bulk and single-cell RNA-seq
ORIGINAL RESEARCH
21 May 2026
Identification of a lactylation-related gene signature in microsatellite stable gastric cancer based on bulk and single-cell RNA-seq
Zhong-Tai Lin, 4 more and Liang-Jie Chi
BackgroundMicrosatellite stable (MSS) gastric cancer (GC) responds poorly to immunotherapy and exhibits heterogeneous outcomes. Histone lactylation plays a critical role in cancer progression. However, the prognostic and therapeutic potential of a lactylation-related gene signature (LRGS) in MSS GC remains largely unexplored.MethodsData of MSS GC patients were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. Consensus clustering based on lactylation-related gene expression profiles was performed to stratify patients. We further constructed the LRGS using machine learning algorithms. We also assessed its correlations with clinicopathological parameters, the tumor microenvironment, and chemosensitivity. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was employed to predict potential responses to immunotherapy. Single-cell analysis, cell-cell communication analysis, in silico knockout, and immunohistochemical validation were integrated to explore the functional roles of key genes.ResultsConsensus clustering uncovered two clusters with significantly different overall survival outcomes. A nine-gene LRGS was established and effectively stratified patients into high- and low-risk groups. The high-risk group displayed an immunosuppressive microenvironment, reduced chemosensitivity, and higher TIDE scores. Single-cell analysis revealed that LRGS scores were highest in cancer-associated fibroblasts (CAFs), with APOD and SERPINE1 highly expressed in PDGFRA+ CAFs and CA9+ CAFs, respectively. Cell-cell communication analysis showed that these two CAF subtypes exhibited distinct signaling patterns via the COLLAGEN and MIF pathways. In silico knockout further validated that APOD and SERPINE1 are essential for matrix remodeling and hypoxia adaptation in their respective CAF subtypes. Immunohistochemical analysis confirmed elevated protein levels of APOD and SERPINE1 in MSS GC.ConclusionsThis study developed and validated a robust LRGS for MSS GC. This signature facilitates accurate prognosis prediction and shows potential to predict responses to both chemotherapy and immunotherapy.

2,554 views

2 citations

ORIGINAL RESEARCH
21 May 2026
AI-based pathomics model predicts regulatory T cell infiltration and radiotherapy response in IDH-wild-type glioblastoma
Shaoli Peng, 13 more and Mingwei Zhang

2,125 views

Tumor-immune spatiotemporal co-evolution as a paradigm for overcoming therapy resistance in advanced prostate cancer
REVIEW
11 March 2026
Tumor-immune spatiotemporal co-evolution as a paradigm for overcoming therapy resistance in advanced prostate cancer
Junchao Xue, 1 more and Meng Zhang
Therapeutic resistance in metastatic castration-resistant prostate cancer (mCRPC) is orchestrated not only by tumor-intrinsic genomic alterations but also by dynamic reprogramming of the tumor microenvironment (TME). This review introduces the tumor-immune spatiotemporal co-evolution paradigm, which reframes mCRPC resistance as an ecosystem-level adaptation unfolding across temporal (disease stage) and spatial (niche architecture) dimensions. We synthesize clinical and multi-omics data to map a probabilistic evolutionary trajectory from an immune-permissive state, through suppressive niche consolidation, to a terminal immune desert phenotype. In this review, we systematically apply the Oxford Centre for Evidence-Based Medicine (OCEBM) 2011 criteria to this field, grading all mechanistic claims to explicitly distinguish peer-reviewed, validated findings (Level 1–2b) from speculative hypotheses (Level 3–4), and delineate 5 evidence-graded core conclusions of the tumor-immune co-evolution paradigm. We delineate how spatially organized cancer-associated fibroblast (CAF) subsets architect immunosuppressive niches and engage in reciprocal metabolic symbiosis with tumor cells, and redefine therapeutics as dominant selective pressures that drive clonal-stromal co-selection to explain cross-resistance across treatment modalities. To translate this paradigm, we propose an integrative closed-loop “Dynamic Monitoring—Mechanistic Parsing—Synergistic Intervention” framework, with concrete, clinically actionable strategies grounded in 2024–2025 peer-reviewed prostate cancer research. This framework advocates for longitudinal ecological auditing of the TME to rationally guide mechanistically orthogonal combination therapies. Our objective is to provide a rigorously evidence-based roadmap for transforming mCRPC into a chronically manageable condition through precision ecological intervention, offering a novel, actionable perspective to advance prostate cancer immunotherapy and overcome immune evasion for researchers and clinicians in the field of cancer immunology.

2,261 views

4 citations

ORIGINAL RESEARCH
17 April 2026
The role of R-loop aberrations in lower-grade gliomas: prognostic, immune, and metabolic implications from multi-omics and machine learning analysis
Ronghua Huang, 12 more and Jian Chen

2,086 views

1 citations

ORIGINAL RESEARCH
25 February 2026
BackgroundNeoadjuvant immunochemotherapy is increasingly used for resectable locally advanced gastric cancer (LAGC) and gastroesophageal junction (EGJ) adenocarcinoma, yet the optimal chemotherapy backbone for PD-1 blockade remains unclear. We compared neoadjuvant PD-1 inhibitor plus S-1+oxaliplatin (SOX) versus PD-1 inhibitor plus 5-FU+oxaliplatin+Docetaxel+Leucovorin (FLOT) in a real-world cohort.MethodsThis single-center retrospective study included patients with resectable, HER2-negative LAGC/EGJ adenocarcinoma (cT3–4b, any N+, M0; ECOG 0–1) treated between July 2020 and July 2025. Patients received neoadjuvant PD-1 inhibitor plus SOX or PD-1 inhibitor plus FLOT (3–5 cycles) followed by D2 gastrectomy. The primary endpoint was pathological complete response (pCR). Secondary endpoints included major pathological response (MPR), radiologic response (RECIST v1.1), perioperative outcomes, treatment-related adverse events (CTCAE v5.0), recurrence-free survival (RFS), and overall survival (OS). Survival was analyzed using Kaplan–Meier methods and Cox proportional hazards models.ResultsOverall, 247 patients were enrolled (PD-1+SOX, n=141; PD-1+FLOT, n=106) with comparable baseline characteristics. Radiologic outcomes were similar between groups (ORR: 70.92% vs 66.98%, p=0.507; DCR: 87.23% vs 85.85%, p=0.752). Pathological responses did not differ significantly (pCR: 20.57% vs 16.98%, p=0.477; MPR: 37.59% vs 31.13%, p=0.292). Any-grade treatment-related adverse events occurred in 67.38% and 75.47% of patients, and grade ≥3 events in 19.15% and 26.42%, respectively; no treatment-related deaths occurred. R0 resection rates were high (100% vs 99.06%). Operative time and estimated blood loss were higher in the PD-1+FLOT group (p=0.010 and p=0.040), while postoperative complication rates were comparable. With median follow-up of 21 months (12–52) and 20 months (10–46), there were no significant differences in OS (HR 1.155, 95% CI 0.624–2.138) or RFS (HR 0.805, 95% CI 0.461–1.405). In multivariable analyses, non-MPR was an independent risk factor for both OS and RFS.ConclusionsNeoadjuvant PD-1 inhibitor plus SOX and plus FLOT yielded comparable response rates, survival outcomes, and safety profiles in patients with resectable LAGC/EGJ adenocarcinoma. PD-1+SOX was associated with less operative burden, and MPR remained independently associated with OS and RFS, supporting its value for risk stratification and treatment optimization.
Neoadjuvant PD-1 inhibitor combined with FLOT versus SOX for locally advanced gastric cancer: a retrospective cohort study

1,965 views

5 citations